How should increased appetite or food cravings be managed in a patient taking tirzepatide?

Increased Appetite on Tirzepatide: An Unexpected Finding

If you are experiencing increased appetite or food cravings while taking tirzepatide, this represents an atypical response that contradicts the expected mechanism of action—you should verify medication adherence, rule out counterfeit medication, and consider switching to an alternative GLP-1 receptor agonist if symptoms persist.

Understanding the Paradox

Tirzepatide is specifically designed to reduce appetite and food intake, not increase it. The highest quality evidence demonstrates that tirzepatide:

• Decreases energy intake by approximately 525 kcal per meal compared to placebo at 3 weeks 1
• Reduces overall appetite scores, food cravings, tendency to overeat, perceived hunger, and reactivity to environmental food cues 1
• Ameliorates problematic eating behaviors in patients with type 2 diabetes, with improvements observed throughout 6 months of treatment 2
• Significantly reduces hyperphagia even in genetic obesity conditions like MC4R deficiency 3

Immediate Assessment Steps

When a patient reports increased appetite on tirzepatide, systematically evaluate:

1. Medication verification: Confirm the patient is receiving authentic tirzepatide (note: the "drug label" references 4 in the evidence appear to be for a homeopathic product, not pharmaceutical tirzepatide—this highlights the risk of counterfeit or mislabeled products)

2. Dosing adequacy: Ensure proper dose escalation has occurred (starting at 2.5 mg weekly, titrating upward to therapeutic doses of 5-15 mg)

3. Timing of symptoms: Determine if appetite increased:

   • Before reaching therapeutic doses (may need further titration)
   • After initial improvement (possible tolerance development)
   • From treatment initiation (suggests non-response)

4. Concurrent medications: Review for drugs that may increase appetite (corticosteroids, antipsychotics, certain antidepressants)

Important Caveat: Tolerance Patterns

One case report 3 documented an adolescent with MC4R deficiency who initially experienced substantial reduction in hyperphagia on tirzepatide, but hunger scores began increasing again after 12 weeks, approaching pre-treatment levels by 28 weeks. Notably, weight loss continued despite returning hunger. This suggests:

• Some patients may develop partial tolerance to appetite-suppressing effects
• Weight loss can persist even when appetite suppression wanes
• Addition of metformin helped re-establish appetite control in this case

Management Algorithm

If appetite increases on tirzepatide:

1. First 12 weeks of treatment:

   • Continue dose escalation to maximum tolerated dose (up to 15 mg weekly)
   • Counsel that appetite effects typically manifest within first 3 months 2

2. After 12+ weeks at therapeutic dose:

   • Consider adding metformin (demonstrated benefit for appetite control when tirzepatide effects waned 3)
   • Evaluate if weight loss is still occurring despite increased appetite
   • If no weight loss and persistent increased appetite: switch to alternative therapy

3. Alternative medication considerations:

   • Switch to a GLP-1 receptor agonist (semaglutide, liraglutide) which have higher certainty evidence for cardiovascular and kidney benefits 5
   • Consider combination therapy with SGLT-2 inhibitors (can be combined with tirzepatide 5)

Clinical Context from Guidelines

The 2025 BMJ guideline 5 emphasizes that when choosing between GLP-1 receptor agonists and tirzepatide, clinicians should weigh higher certainty of cardiovascular and kidney benefits (offered by GLP-1 receptor agonists) against larger weight loss benefits (offered by tirzepatide). If a patient is not experiencing the expected appetite suppression with tirzepatide, the rationale for choosing it over a GLP-1 receptor agonist diminishes significantly.

Key Pitfall to Avoid

Do not assume increased appetite is "normal" or acceptable on tirzepatide. This medication's primary mechanism involves appetite reduction through decreased food intake, reduced food cravings, and increased satiety 1, 6, 7. Persistent increased appetite suggests either inadequate dosing, medication authenticity issues, or true non-response requiring medication change.